Epidarex Capital announced its latest fund launch totaling £102 million ($128 million) that includes a commitment from the British Business Bank’s Enterprise Capital Funds program.
The fund, Epidarex Capital III UK, will invest in new life science companies from emerging research hubs across the U.K., including spinouts from highly regarded universities. The typical investments will range from £2 million to £5 million.
The Enterprise Capital Fund (ECF) program centers on early stage venture capital and since its inception has committed £1.36 billion to facilitate finance to 540 smaller U.K. high growth . . .
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters, with a convenient pay-as-you-go monthly subscription.
Annual subscriptions save you 10% and also get you access toAlternatives Watch Researcharticles and ourAnnual Investor Compendium!